Hämäläinen Riikka H
Research Programs Unit, Molecular Neurology, Biomedicum-Helsinki, University of Helsinki, Helsinki, Finland.
Methods Enzymol. 2014;547:399-415. doi: 10.1016/B978-0-12-801415-8.00019-9.
Mitochondrial disease due to mutations in the mitochondrial DNA (mtDNA) is a common cause of human inherited disorders. Targeted modification of the mitochondrial genome has not succeeded with the current transgenic technologies. Furthermore, readily available cultured patient cells often do not manifest the disease phenotype. Therefore, pathogenic mechanisms underlying these disorders remain largely unknown, as the lack of model systems has hampered mechanistic studies. Stem cell technology has opened up new ways to use patient cells in research, through generation of induced pluripotent stem cells (iPSCs) and differentiation of these to disease-relevant cell types, including, for example, human neurons and cardiomyocytes. Here, we discuss the use of iPSC-derived models for disorders with mtDNA mutations.
线粒体DNA(mtDNA)突变导致的线粒体疾病是人类遗传性疾病的常见病因。利用当前的转基因技术对线粒体基因组进行靶向修饰尚未成功。此外,容易获得的培养患者细胞通常不表现出疾病表型。因此,由于缺乏模型系统阻碍了机制研究,这些疾病的致病机制在很大程度上仍然未知。干细胞技术通过诱导多能干细胞(iPSC)的产生以及将这些细胞分化为与疾病相关的细胞类型,包括例如人类神经元和心肌细胞,为在研究中使用患者细胞开辟了新途径。在此,我们讨论使用iPSC衍生模型研究mtDNA突变相关疾病。